首页 | 本学科首页   官方微博 | 高级检索  
     


On future non-medical costs in economic evaluations
Authors:Liljas Bengt  Karlsson Göran S  Stålhammar Nils-Olov
Affiliation:1. AstraZeneca, M?lndal, Sweden;2. LUCHE (Lund University Centre for Health Economics), Lund, Sweden;3. Department of Economics, Lund University, Lund, Sweden;4. AstraZeneca Sverige, S?dert?lje, Sweden;5. Department of Economics, G?teborg University, G?teborg, Sweden
Abstract:
Economic evaluation in health care is still an evolving discipline. One of the current controversies in cost‐effectiveness analysis regards the inclusion or exclusion of future non‐medical costs (i.e. consumption net of production) due to increased survival. This paper examines the implications of a symmetry rule stating that there should be consistency between costs included in the numerator and utility aspects included in the denominator. While the observation that no quality‐adjusted life year (QALY) instruments explicitly include consumption and leisure seems to give support to the notion that future non‐medical costs should be excluded when QALYs are used as the outcome measure, a better understanding of what respondents actually consider when reporting QALY weights is required. However, the more fundamental question is whether QALYs can be interpreted as utilities. Or more precisely, what are the assumptions needed for a general utility model also including consumption and leisure to be consistent with QALYs? Once those assumptions are identified, they need to be experimentally tested to see whether they are at least approximately valid. Until we have answers to these areas for future research, it seems premature to include future non‐medical costs. Copyright © 2007 John Wiley & Sons, Ltd.
Keywords:economic evaluation  future costs  cost‐effectiveness analysis  QALYs  welfare economics
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号